Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: James P Anderson who wrote (692)	7/11/1999 11:15:00 PM
From: Street Walker	Respond to of 5582

Buyers of the recent volume James, there have always been buyers of GUMM and many on the sidelines waiting to buy, as soon as it broke out of its $10 trading range. When it broke out of the range, it triggered those individuals buying. Many have known about ZICAM and have waited for the beginning of the cold season to begin establishing a major position. One of the buyers in the recent price movement was a mutual fund. They wanted to buy a head of everyone else who will begin accumulating in another month. I made a promise not to reveal the name of the fund, but suffice it to say, everyone would recognize the name. I don't know if they are through buying. Individual investors have also been waiting for the beginning of the cold season to buy GUMM. Some of them probably saw the movement and began to buy a little early as well. Everyone who has followed GUMM knows that it is going to make a tremendous move throughout the upcoming cold season. Then coupled with the potential Nicorette Gum contract(s) it will go up higher. Fourth quarter earnings posted next April are going to be phenominal. This is a stock for investors. The people I personally know who have been making large investments, are mainly doctors and pharmacists who realize the impact of ZICAM. My own patients who have elimated colds using Zicam have become shareholders and staunch believers. We are in for a very long term investment, in which this is barely the beginning. Some shorts had a certain stop-out and covered during the recent small movement. In the past, the major short players of GUMM have been very stubborn at covering. They did not cover when the stock ran up to $15 earlier in the year. Shorts have said in the past that $15 would be their stop out. From what I gather, it is believed that the current short squeeze that will occur later this week and the week following will be do to a letter that is being sent out by a clearing firm named RPR. This clearing firm holds around 4 million shares of GUMM for Gun Allen's clients. They have loaned shares to other firms for their clients to short. Gun Allen is changing clearing firms and so RPR has to inform the other firms that they need the loaned shares back. This letter is suppose to be recieved by the firms on Monday. Then the firms will notify the stubborn individuals that they are required to cover. So to answer your question straight out, I think very few short shares have been covered during the recent price movement. Some of the volume has been from longs buying in anticipation of the major short squeeze which will occur later this week and going into next week. This coupled by others going long because of wanting to own a piece of "zicam" before the cold season, and others buying out of anticipation of a gigantic Nicorette contract, bodes well for those who are long the stock for the foreseeable future. Regards, S.W.

To: James P Anderson who wrote (692)	7/11/1999 11:25:00 PM
From: Street Walker	Read Replies (1) \| Respond to of 5582

There are 30,000 - 50,000 stores who will be advertising ZICAM in their weekly newspaper inserts. These include Walmart, K-mart, Target, Albertson's (second largest grocery store in the US), Rite Aide, and the list goes on and on. ADVERTISING by these marketing powerhouses will attract buyers of Zicam. Ancedotal/testimonial evidence that Zicam eliminates colds from 10-14 days to around 2 days will spread like wildfire through families, networks of friends, and people at the work place. This is happening because Zicam does eliminate the cold to an average of 1.5 days used as directed. One clinical study has been completed. Another study, being conducted at a major univeristy in California will have their's complete next month. Both studies will be submitted for publication. Once the "scientific" community has been informed, GUMM shares will become extrememly valuable. I'm glad to own before this all happens. GUMM's NET PROFIT per sale is around $1.80 So we are talking extremely high profit margins for the very best product used against the most common illness - the common cold. As time goes on, we will see continued buying by Hedge Funds and other mutual funds. This is history in the making in which I'm glad to be an investor early on. In following years, Zicam will penetrate the $3 Billion US cold market further. Its also a big world out there and cold sufferers in other countries will have access to Zicam after its launch in America. $ Net profit: $1.80 per sale x number of colds. Regards, S.W.